Cholangiocarcinoma Trial Landscape (November 2026)

Last updated: Nov 19, 2026 · Built by a patient who got tired of scrolling ClinicalTrials.gov

Overview

284
Recruiting
51
Phase 1
181
Phase 2
24
Phase 3
3
Phase 4

Active interventional trials with status RECRUITING or NOT_YET_RECRUITING. A multi-phase trial (e.g. 1/2) is counted in each of its phases.

Looking for cholangiocarcinoma trials matched to your specific case?

Biomarkers, stage, prior treatments — get a ranked shortlist in minutes.

Find My Matches →

Mechanism Breakdown

Recruiting trials grouped by drug class. Trials with unclassifiable or non-therapeutic interventions are excluded from this view.

Checkpoint inhibitor
88
Antibody-drug conjugate (ADC)
17
Bispecific antibody
16
Chemotherapy
14
Monoclonal antibody
9
Other / unclassified
9
Tyrosine kinase inhibitor (TKI)
8
CAR-T cellular therapy
6
Small-molecule inhibitor
5
Vaccine (other)
3
Other inhibitor
3
Oncolytic virus
2

Recently Updated Trials

NCTPhaseTitleMechanism
NCT077159031Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump TherapyProteasome -- proteasome inhibitor (carfilzomib)
NCT069032732Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk CholangiocarcinomaPD-1 -- immune checkpoint inhibitor (monoclonal antibody)
NCT078298742Cryoablation Combined With QL1706 (Iparomlimab/Tuvonralimab) Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer.PD-1 + CTLA-4 -- bispecific antibody; VEGFR + other kinases -- multi-kinase inhibitor (TKI)
NCT079380212HLX22 Plus Serplulimab and Trastuzumab or Pertuzumab in HER2-Low Advanced Gastrointestinal CancersHER2 -- anti-HER2 monoclonal antibody (trastuzumab/pertuzumab) combined with PD-1 immune checkpoint blockade (serplulimab) and HLX22 (Unknown mechanism)
NCT079386452PARP Inhibition for Biliary Tract Cancer With Mutations in Core and Non-Core Homologous Recombination Deficiency GenesPARP1/2 -- PARP inhibitor combined with PD-L1 immune checkpoint blockade (PARP inhibitor + anti-PD-L1 immunotherapy)

Top Sponsors

SponsorRecruiting trials
Fudan University14
Shanghai Zhongshan Hospital10
Tianjin Medical University Cancer Institute and Hospital8
Peking Union Medical College Hospital8
M.D. Anderson Cancer Center6

Geographic Distribution

Countries/regions with the most active trial sites for cholangiocarcinoma. A multi-site trial is counted once per country/region.

China
133
United States
73
France
16
South Korea
15
Italy
14
Taiwan
12
United Kingdom
11
Japan
11
Germany
11
Netherlands
10

Emerging Classes

Phase-1 trials whose listed start date falls within the last 12 months — the leading edge of the field.

StartNCTTitleMechanism
Dec 2026NCT07594067TCR1188-ABC Cells in KRAS-mutated CancersKRAS mutant peptides -- T cell receptor (TCR) engineered T cells
Nov 23, 2026NCT07715903Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump TherapyProteasome -- proteasome inhibitor (carfilzomib)
Nov 2026NCT07738939IKS04 Regimen in Advanced Solid Tumors That Express CA242CA242 -- antibody-drug conjugate (ADC)
Sep 15, 2026NCT07632235A Multicenter, Prospective, Randomized, Open-label Phase Ib/II Study of Celecoxib Plus Pembrolizumab and Gemcitabine/Cisplatin Versus Pembrolizumab and Gemcitabine/Cisplatin in Patients With CK5/6-High Unresectable Locally Advanced or Metastatic Intrahepatic CholangiocarcinomaCOX-2 -- selective inhibition (NSAID); PD-1 -- immune checkpoint blockade (monoclonal antibody)
Sep 2026NCT07796997GI-06: The Impact of Perioperative Hydrocortisone on Patients Undergoing Partial PancreatectomyGlucocorticoid receptor -- anti-inflammatory and immunosuppressive effects (steroid hormone)
May 2026NCT07614061Safety and Efficacy of CD160-Enhanced Autologous Antigen-Specific T-Cells (BTC-Ag-T) in Advanced Biliary Tract CancerCD160 -- autologous antigen-specific T-cell therapy
Mar 27, 2026NCT07107750Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract CancerIRAK4 -- small molecule inhibitor (Emavusertib) + chemotherapy (Gemcitabine, Cisplatin) + PD-L1 -- immune checkpoint inhibitor (Durvalumab)
Mar 2, 2026NCT07641036Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract CancerHER2 + CEACAM5 -- dual-target chimeric antigen receptor natural killer cells (CAR-NK)

You've seen the cholangiocarcinoma landscape. Now find the trials that fit your case.

Enter biomarkers, stage, and prior treatments — get ranked matches with eligibility breakdown in minutes.

Find My Matches →

Source: ClinicalTrials.gov, synced daily. Aggregated by ClinTrialFinder.